An investigation of the differential therapeutic effects of romosozumab on postmenopausal osteoporosis patients with or without rheumatoid arthritis complications: a case–control study
Authors:
- Kosuke EbinaKEKosuke Ebina
- Masafumi KashiiMKMasafumi Kashii
- Hideki TsuboiHTHideki Tsuboi
- Gensuke OkamuraGOGensuke Okamura
- Akira MiyamaAMAkira Miyama
- Yuki EtaniYEYuki Etani
- Takaaki NoguchiTNTakaaki Noguchi
- Makoto HiraoMHMakoto Hirao
- Taihei MiuraTMTaihei Miura
- Yuji FukudaYFYuji Fukuda
- Takuya KuriharaTKTakuya Kurihara
Open Access
- 31 January 2024
- journal article
- research article
- Published by Springer Nature in Osteoporosis International
- Vol. 35 (5) , 841-849
Abstract
Summary The impact of ROMO on the width of anabolic windows and the increase in BMD was reduced in the RA group compared to the non-RA group, and this reduction was associated with correlations to RA-related factors. Purpose To investigate the effects of romosozumab (ROMO) in postmenopausal osteoporosis, with and without comorbid rheumatoid arthritis (RA). Methods In this retrospective, case-controlled, multicenter study, 171 postmenopausal patients who did not receive oral glucocorticoid, comprising 59 in the RA group and 121 in the non-RA group, received uninterrupted ROMO treatment for 12 months. Propensity score matching was employed to ensure comparability in clinical backgrounds, resulting in 41 patients in each group. Baseline characteristics were as follows: overall (mean age, 76.3 years; T-score of lumbar spine (LS), − 3.0; 45.1% were treatment-naive for osteoporosis); RA group (anti-cyclic citrullinated peptide antibody (ACPA) positivity, 80.5%; titer, 206.2 U/ml; clinical disease activity index (CDAI), 13.6; health assessment questionnaire disability index (HAQ-DI), 0.9). Bone mineral density (BMD) and serum bone turnover markers were monitored over a 12-month period. Results The rate of increase in the bone formation marker, PINP, and the rates of decrease in the bone resorption marker, TRACP-5b, exhibited a trend toward smaller changes in the RA group compared to the non-RA group, implying a smaller anabolic window. After 12 months, the RA group displayed lower BMD increases in the LS (9.1% vs. 12.6%; P = 0.013) and total hip (2.4% vs. 4.8%; P = 0.025) compared to the non-RA group. Multiple regression analysis in the all RA group (n = 59) for the association between RA-specific factors and 12-month BMD changes revealed negative correlations between ACPA titer and LS BMD and between HAQ-DI and femoral neck BMD. Conclusions The efficacy of ROMO may be attenuated by RA-related factors.Keywords
Funding Information
- Osaka University
This publication has 27 references indexed in Scilit:
- Brief Report: Tumor Necrosis Factor and Interleukin‐6 Differentially Regulate Dkk‐1 in the Inflamed Arthritic JointArthritis & Rheumatology, 2015
- Sustained Modeling-Based Bone Formation During Adulthood in Cynomolgus Monkeys May Contribute to Continuous BMD Gains With DenosumabJournal of Bone and Mineral Research, 2015
- Romosozumab in Postmenopausal Women with Low Bone Mineral DensityNew England Journal of Medicine, 2014
- IL-6 negatively regulates osteoblast differentiation through the SHP2/MEK2 and SHP2/Akt2 pathways in vitroJournal of Bone and Mineral Metabolism, 2013
- Functions of the osteocyte network in the regulation of bone massCell and tissue research, 2013
- Investigation of the freely available easy-to-use software ‘EZR’ for medical statisticsBone Marrow Transplantation, 2012
- Japanese 2011 guidelines for prevention and treatment of osteoporosis—executive summaryArchives of Osteoporosis, 2012
- Induction of osteoclastogenesis and bone loss by human autoantibodies against citrullinated vimentinJournal of Clinical Investigation, 2012
- Serum TRACP 5b Is a Useful Marker for Monitoring Alendronate Treatment: Comparison With Other Markers of Bone TurnoverJournal of Bone and Mineral Research, 2005
- Vertebral fracture assessment using a semiquantitative techniqueJournal of Bone and Mineral Research, 1993